Investing.com -- Deutsche Bank struck a more upbeat tone on European pharmaceuticals, upgrading Alvotech to Buy from Hold while keeping its price target at $14. Shares in Alvotech rose 4.6% in U.S.
Greenlight Capital's 13F portfolio rose to $2.33B in Q2 2025. Check out the key new stakes and major increases in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback